RxDoctor Payments Data

Abhishek Sinha, MD

Interventional Cardiology · Valencia, CANPI 1902971567

Payments from drug & device makers

$7,551in general payments, 2019–2025

Across 249 payments — averaging $30.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$2K
  • Edwards Lifesciences$1K
  • Novartis$1K
  • Abbott$660
  • Boston Scientific$431
  • Merck$223
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$4306%
  • Travel & lodging$1,64522%
  • Food & beverage$5,46272%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,551 in reported general payments places this provider in the 40th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$179,537
Medicare patients
341
Services billed
1,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban200$262,430
EntrestoSacubitril/Valsartan110$126,595
XareltoRivaroxaban27$36,069
BrilintaTicagrelor30$26,563
JardianceEmpagliflozin12$18,410
Metoprolol Succinate258$4,049
Amiodarone Hcl55$2,306
ClopidogrelClopidogrel Bisulfate145$1,745
Atorvastatin Calcium125$1,258
Losartan Potassium96$1,064
Amlodipine Besylate83$784
Valsartan14$650
Diltiazem 24hr Er (Cd)Diltiazem Hcl22$639
Nebivolol Hcl15$631
Ezetimibe20$587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$148$262,430200 claims
NovartisEntresto$1,091$126,595110 claims
Johnson & JohnsonXarelto$43$36,06927 claims
AstraZenecaBrilinta$175$26,56330 claims
Boehringer IngelheimJardiance$116$18,41012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Valencia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →